FIELD: biotechnology.
SUBSTANCE: following is presented: antibodies to CLDN18.2 or antigen-binding fragments thereof and a method of their preparation and use, a nucleic acid molecule encoding antibodies or antigen-binding fragments thereof, conjugates for determining the amount of CLDN18.2 or determining whether a tumor is treatable with antitumor therapy targeting CLDN18.2, expression vector, host cell. And also the following is indicated: immunoconjugate, chimeric antigen receptor, pharmaceutical composition, kits for determining the amount of CLDN18.2, a method of reducing the level of expression of CLDN18.2, a method of killing a tumor cell, a method of treating a tumor, kits for determining whether a tumor is treatable with antitumor therapy aimed at on CLDN18.2
EFFECT: prevention and/or treatment of a tumor.
51 cl, 14 tbl, 8 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER DIAGNOSIS | 2013 |
|
RU2661772C2 |
| COMBINED THERAPY WITH CLAUDINE 18.2 ANTIBODIES FOR CANCER TREATMENT | 2014 |
|
RU2699549C2 |
| COMBINATION THERAPY USING ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2789478C2 |
| COMBINED THERAPY WITH USE OF CLAUDIN 18,2 ANTIBODIES FOR CANCER TREATMENT | 2013 |
|
RU2662066C2 |
| BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN 6 OR CLAUDIN 18.2 AND CD3 FOR THE TREATMENT OF ONCOLOGICAL DISEASES WITH CLAUDIN EXPRESSION | 2017 |
|
RU2798988C2 |
| COMBINED THERAPY USING THE ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2665321C2 |
| ANTIBODIES AGAINST PD-1 AND THEIR USE | 2018 |
|
RU2788616C2 |
| AGENTS FOR TREATMENT OF CLAUDIN EXPRESSING CANCER DISEASES | 2013 |
|
RU2678127C2 |
| ANTIBODIES FOR TREATMENT OF HEPATITIS B INFECTION AND RELATED DISEASES | 2018 |
|
RU2765878C2 |
| ANTIBODIES AGAINST CTLA4 AND THEIR USE | 2017 |
|
RU2779312C2 |
